← /news·[FEED]·JUN 09·2 min read

Novo's Wegovy Pill Still Leads the GLP-1 Pill Market as Lilly's Foundayo Launches

Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Foundayo, Eli Lilly's GLP-1 pill, according to MarketWatch.

$Staff·NewsNTech·[NVO] [LLY]

share //

$ cat source.txt

editorial.local

← back to the feed Subscribe free

// related, decompiled

Behind-the-Meter Power Is the Real Story in the Tachyon9-Nidar Offtake for North Dakota's Nakota AI Campus

In AI infrastructure the binding constraint is no longer chips or capital, it is megawatts on the meter, and the utility interconnection queue can stall a new campus for years. That is the

Staff·4 minJUN 22

[FEED]02

AI May Be Masking a Literacy Crisis in the U.S. Workforce, Experts Warn

Millions of working Americans struggle to read at a functional level, and artificial intelligence may be helping conceal it.

Staff·2 minJUN 16

[FEED]03

Inside the Tachyon9-Nidar MOU: How a 100 MW Anchor Lease Underpins a 1 GW AI-Campus Plan

Tachyon9 Corporation has signed a binding 15-year memorandum of understanding with Nidar Infrastructure Limited, the parent and majority shareholder of Indian hyperscale operator Yotta Data Services, to anchor the first …

Staff·4 minJUN 15